Journal Article10.7326/0003-4819-137-5_PART_2-200209031-00002
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002
Henry Masur,Jonathan E. Kaplan,King K. Holmes,Beverly Alston,Miriam J. Alter,Neil M. Ampel,Jean Anderson,A. Cornelius Baker,David A Barr,John G. Bartlett,John E. Bennett,Constance A. Benson,William A. Bower,Samuel A. Bozzette,John T. Brooks,Victoria A. Cargill,Kenneth G. Castro,Richard E. Chaisson,David A. Cooper,Clyde S. Crumpacker,Judith S. Currier,Kevin M. DeCock,Lawrence Deyton,Scott F. Dowell,W. Lawrence Drew,William Duncan,Mark S. Dworkin,Clare A. Dykewicz,Robert W Eisinger,Tedd Ellerbrock,Wafaa El-Sadr,Judith Feinberg,Kenneth A. Freedberg,Keiji Fukuda,Hansjakob Furrer,Jose M. Gatell,John W. Gnann,Mark J. Goldberger,Sue Goldie,Eric P. Goosby,Fred M. Gordin,Peter A. Gross,Rana Hajjeh,Richard Hafner,Diane Havlir,S D Holmberg,David R. Holtgrave,Thomas M. Hooton,Douglas A. Jabs,Mark A. Jacobson,Harold Jaffe,Edward N. Janoff,Jeffrey M. Jones,Dennis D. Juranek,Mari M. Kitahata,Joseph A. Kovacs,Catherine Leport,Myron J. Levin,Juan C. Lopez,Jens D Lundgren,Michael Marco,Eric Mast,Douglas L. Mayers,Lynne M. Mofenson,Julio Montaner,Richard A. Moore,Thomas Navin,James D. Neaton,Charles Nelson,Joseph F. O'Neill,Joel Palefsky,Alice Pau,Phil Pellett,John P. Phair,Steve Piscitelli,Michael A. Polis,Thomas C. Quinn,William C. Reeves,Peter Reiss,David Rimland,Anne Schuchat,Cynthia L. Sears,Leonard B. Seeff,Kent A. Sepkowitz,Kenneth E. Sherman,Thomas G. Slama,Elaine M. Sloand,Stephen A. Spector,John A. Stewart,David L. Thomas,Timothy M. Uyeki,Russell Van Dyke,M. Elsa Villarino,Anna Wald,D. Heather Watts,L. Joseph Wheat,Paige L. Williams,Thomas C. Wright +97 more
662
TL;DR: This fourth edition of the guidelines for preventing opportunistic infections (OIs) among persons infected with human immunodeficiency virus (HIV) is intended for clinicians and other health-care providers who care for HIV-infected persons.
read more
Abstract: In 1995, the U.S. Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA) developed guidelines for preventing opportunistic infections (OIs) among persons infected with human immunodeficiency virus (HIV); these guidelines were updated in 1997 and 1999. This fourth edition of the guidelines, made available on the Internet in 2001, is intended for clinicians and other health-care providers who care for HIV-infected persons. The goal of these guidelines is to provide evidence-based guidelines for preventing OIs among HIV-infected adults and adolescents, including pregnant women, and HIV-exposed or infected children. Nineteen OIs, or groups of OIs, are addressed, and recommendations are included for preventing exposure to opportunistic pathogens, preventing first episodes of disease by chemoprophylaxis or vaccination (primary prophylaxis), and preventing disease recurrence (secondary prophylaxis). Major changes since the last edition of the guidelines include 1) updated recommendations for discontinuing primary and secondary OI prophylaxis among persons whose CD4+ T lymphocyte counts have increased in response to antiretroviral therapy; 2) emphasis on screening all HIV-infected persons for infection with hepatitis C virus; 3) new information regarding transmission of human herpesvirus 8 infection; 4) new information regarding drug interactions, chiefly related to rifamycins and antiretroviral drugs; and 5) revised recommendations for immunizing HIV-infected adults and adolescents and HIV-exposed or infected children.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.
TL;DR: The ability of hospital ventilation systems to filter Aspergillus and other fungi following a building implosion and the impact of bedside design and furnishing on nosocomial infections are investigated.
3.3K
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
TL;DR: The most recent version of the guidelines for the prevention and treatment of opportunistic infections (OI) in HIV-infected adults and adolescents was published in 2002 and 2004, respectively as mentioned in this paper.
1.6K
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
Marcie Tomblyn,Tom Chiller,Hermann Einsele,Ronald E. Gress,Kent A. Sepkowitz,Jan Storek,John R. Wingard,Jo Anne H. Young,Michael Boeckh +8 more
TL;DR: Changes include the recommendations for PCV rather than PPSV-23 for pneumococcal vaccination, starting some vaccinations earlier post-transplant, and the addition of recommendations for Varivax, HPV vaccine, and (the non-use of) Zostavax vaccine are included.
1.6K
•Journal Article
Chronic obstructive pulmonary disease surveillance--United States, 1971-2000.
TL;DR: In this article, the authors present national data regarding objectively determined COPD (1971-1994), COPD-associated activity and functional limitations (1980-1996), self-reported COPD prevalence, COPD physician office and hospital outpatient department visits, and COPD hospitalizations, and deaths.
1.5K
Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005
Paul A. Jensen,Lauren A. Lambert,Michael F. Iademarco,Renee Ridzon +3 more
- 30 Dec 2005
TL;DR: The threat of MDR TB is decreasing, and the transmission of M. tuberculosis in health-care settings continues to decrease because of implementation of infection-control measures and reductions in community rates of TB.
References
A Prospective Randomized Trial of Four Three-Drug Regimens in the Treatment of Disseminated Mycobacterium avium Complex Disease in AIDS Patients: Excess Mortality Associated with High-Dose Clarithromycin
David L. Cohn,E. J. Fisher,Grace Peng,J. S. Hodges,J. Chesnut,Carroll Child,B. Franchino,C. L. Gibert,Wafaa El-Sadr,Richard Hafner,Joyce A. Korvick,M. Ropka,Leonid B. Heifets,J. Clotfelter,D. Munroe,Charles R. Horsburgh +15 more
TL;DR: Bacteriologic outcomes were similar among treatment groups and the maximum dose of clarithromycin should be 500 mg b.i.d. in treating MAC disease in AIDS patients.
Interim Guidelines for Management of Abnormal Cervical Cytology
Robert J. Kurman,Donald Eari Henson,Arthur L. Herbst,Kenneth L. Noller,Mark Schiffman,Thomas A. Bonfiglio,Henry W. Buck,Christopher P. Crum,John P. Curtin,Mitchell D. Greenberg,Kenneth D. Hatch,Donald E. Henson,A. Bennett Jenson,Peter R. Johnson,Howard W. Jones,Harold A. Kaminetsky,Luella Klein,Leopold G. Koss,Burton A. Krumholz,Nancy C. Lee,Ronald D. Luff,Jeanne S. Mandelblatt,Richard Reid,Ralph M. Richart,Thomas V. Sedlacek,Charles Sneiderman,Diane Solomon,Mark H. Stoler,Floyd Taub,Edward L. Trimble,Ernest F. Tucker,Leo B. Twiggs,Edward J. Wilkinson,Barbara Atkinson,Harvey E. Averette,William T. Creasman,Sandra Fryhofer,Julie Noy,Mary L. Nielsen,Kenneth L. Noller,Robert C. Park,Douglas Westhoff +41 more
TL;DR: In recent years it has become evident that the cost and morbidity associated with the detection and treatment of low-grade cervical lesions have escalated, probably increasing the likelihood of women developing cervical cancer.
USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
David Lanier,Neil Schram,Ellen C. Cooper,Kenneth A. Freedberg,Kenneth H. Mayer,Richard Blinkhorn,Jerrold J. Ellner,Fred Angulo,Ruth L. Berkelman,Robert F. Breiman,Ralph T. Bryan,James W. Buehler,Blake Caldwell,Kenneth G. Castro,James E. Childs,Susan Chu,Carol A. Ciesielski,D. Peter Drotman,Brian R. Edlin,Tedd V. Ellerbrock,Patricia L. Fleming,Larry Geiter,Rana A. Hajjeh,Debra L. Hanson,Scott D. Holmberg,James M. Hughes,Harold W. Jaffe,Jeffrey L. Jones,Dennis D. Juranek,Jonathan E. Kaplan,David W. Keller,William J. Martone,Michael M. Mc Neil,Bess Miller,Thomas R. Navin,Verla S. Neslund,Stephen M. Ostroff,Philip E. Pellett,Robert W. Pinner,Susan E. Reef,William C. Reeves,Russell L. Regnery,Frank O. Richards,Martha F. Rogers,Lawrence B. Schonberger,R. J. Simonds,Patricia M. Simone,Dawn K. Smith,Steven L. Solomon,Richard A. Spiegel,John A. Stewart,David L. Swerdlow,Suzanne D. Vernon,John W. Ward,Joyce J. Neal,Walter F. Schlech,Catherine M. Wilfert,Robert Horsburgh,John Mc Gowan,David Rimland,Mark Goldberger,Carol Braun Trapnell,David Barr,Gabriel Torres,Harrison C. Stetler,Peter A. Gross,Wafaa El-Sadr,Deborah J. Cotton,Wayne L. Greaves,John Bartlett,Richard E. Chaisson,Judith Feinberg,Thomas C. Quinn,Joseph Horman,Kristine Mac Donald,Mary E. Wilson,Rhoda S. Sperling,Alberto Avandano,A. Cornelius Baker,Anthony R. Kalica,Joseph A. Kovacs,Henry Masur,Michael A. Polis,Steven M. Schnittman,Charles Nelson,John P. Phair,Constance A. Benson,Bob Wood,Walter T. Hughes,Benjamin J. Luft,Newton E. Hyslop,Richard J. Whitley,Neil M. Ampel,W. Lawrence Drew,Jane E. Koehler,Constance B. Wofsy,James D. Neaton,Fred R. Sattler,Sharon A. Baker,Lawrence Corey,King K. Holmes,William G. Powderly +101 more
The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.
Sue J. Goldie,Karen M. Kuntz,Milton C. Weinstein,Kenneth A. Freedberg,Mark L. Welton,Joel M. Palefsky +5 more
TL;DR: Screening HIV-positive homosexual and bisexual men for ASIL and anal SCC with anal Pap tests offers quality-adjusted life expectancy benefits at a cost comparable with other accepted clinical preventive interventions.